CSL – Macquarie rates the stock as Neutral
CSL has entered into a licensing agreement with uniQure for exclusive rights to a gene therapy product for haemophilia B.
Read MoreTag: CSL
CSL – Citi rates the stock as Upgrade to Buy from Neutral
With the shares having underperformed the broader market by no less than -19% over the month past, including a noticeable drubbing in yesterday’s session, Citi analysts have upgraded CSL to Buy from Neutral.
Read MoreDo Less Risky Stock Market Exposures Really Exist?
With a sense of raw panic descending on global stock markets, the question is whether there are any truly safe havens in terms of remaining exposed to equities?
Read MoreCSL – Citi rates the stock as Upgrade to Buy from Neutral
A brave team of healthcare analysts at Citi has upgraded CSL to Buy from Neutral if only because the share price continues to weaken. Citi has kept the $332 price target intact, while forecasting double-digit percentages growth in EPS for each of the following three years.
Read MoreCSL – UBS rates the stock as Buy
Strong plasma industry data out of the US comes as no surprise to the broker given the numbers run on a three month lag and CSL’s first half result has already told the story. The broker believes the data likely reflect ongoing movement of product from the rest of the world into the US, where prices ar higher, rather than being a proxy for plasma supply growth.
Read MoreCSL – Morgans rates the stock as Hold
First half results were better than Morgans expected. Immunoglobulin growth continues to impress and Seqirus sales were robust.
Read More“Well-Positioned” CSL Lifts H1 Earnings 11%
A rather ho-hum reaction from investors yesterday to another solid result from CSL, the current market darling and most expensive share on the ASX.
Read MoreCSL Reaping The Reward Of Foresight
CSL has shown foresight in expanding plasma collection over recent years, enabling significant share in a market where demand for immunoglobulin has run ahead of supply.
Read MoreCSL – Credit Suisse rates the stock as Outperform
A tight market in plasma presents an opportunity in Europe, Credit Suisse notes. The broker suspects the US political environment, where CSL generates 55% of its immunoglobulin revenue, is likely to limit any significant price rises.
Read MoreBullish CSL Hits Record High On Bumper FY19 Profit
CSL’s shares hit an all-time high yesterday after the company issued a bullish outlook statement on top of a very solid 2018-19 result and higher dividend (which was made a lot fatter by the slide in the value of the Aussie dollar in recent weeks).
Read MoreCSL – UBS rates the stock as Buy
The Trump Administration has withdrawn its proposed rebate rule which was intended to stop the practice of pharmacy benefit manager rebates from January 1, 2020. UBS suggests the most likely reason was the cost of implementation.
Read MoreCSL – Morgans rates the stock as Hold
CSL is moving to direct distribution into China after gaining its Good Supply Practice Licence through the acquisition of Guangzhou Junxin Pharmaceutical last year.
Read MoreCSL – Citi rates the stock as Buy
CSL had earlier flagged that transitioning to its own distribution channel in China would have a one-off impact on FY20 financials. On Friday the company quantified this impact in the form of a decline in albumin sales by -US$340-US$370m.
Read MoreCSL – UBS rates the stock as Buy
UBS reviews the commercial opportunity for the company’s reconstituted high-density lipoprotein product. The product is currently in a phase 3 clinical trial with the final result expected in 2022.
Read MoreCSL – Credit Suisse rates the stock as Neutral
Credit Suisse observes specialty sales for CSL Behring have grown around 15% per annum since FY13, driven in part by Kcentra. The broker believes this product is increasingly used off label to reverse other anti-coagulants including NOAC and control bleeding in trauma situations.
Read MoreIf You Could Pick Just One Australian Stock For Your Portfolio, What Would It Be?
Global equities manager, WCM Investment Management (WCM), says the Australian company included in their international portfolio is one of their strongest performers over the past seven years – CSL Limited (ASX: CSL).
Read MoreCSL – Credit Suisse rates the stock as Neutral
Credit Suisse observes the first half result was affected by soft albumin and haemophilia product sales. The broker suspects, with no near-term product launches and potentially softer growth in key specialties, there are questions about the company’s ability to generate sustainable margins.
Read MoreHigh Expectations Hurt CSL
Investors have been left cold despite CSL reporting an interim net profit of $US1.2 billion ($A1.7 billion), a higher dividend and a lift in full-year guidance.
Read MoreCSL – Macquarie rates the stock as Outperform
US flu dose distributions and early-season vaccination rates are up 10% and 6% respectively for the 2018-19 season. Macquarie expects a positive mix shift which will support the near-term outlook for Seqirus.
Read MoreCSL Confirms Guidance, Cans Share Split
CSL shares ended up 2.4% in yesterday’s general rally after CEO, Paul Perreault reaffirmed to the company’s AGM that the company was sticking to previous guidance for a 10-14% increase in annual net profit in 2018-19.
Read MoreCSL In Rude Health Lifts Dividend 26%
CSL has lifted dividends to shareholders by a very sold 26% for the year to June 30 after reporting record sales and profits for the year to June.
Read MoreCSL Provides Trifecta Of Good News
A trifecta of good news from blood products giant CSL yesterday in its 2017-18 first half report.
Read MoreCSL Climbs To New High On Bullish Broker Upgrades
CSL shares hit a new all time high yesterday ahead of the release of its interim results in a fortnight’s time.
Read MoreCSL Bets Big On Heart Attack Treatment
For pharmaceutical companies, spending hundreds of millions of dollars in drug trials is like a mining company investing in a new mine or mineral – investors don’t like the investment for the future and want more money, now.
Read MoreCSL In US Expansion
At one stage in yesterday’s ‘blah’ market shares in blood products giant, CSL were up nearly 5% at $129.16 after it revealed plans to but a US biotech for more than $410 million, if certain performance markers are met over the next 8 years.
Read MoreHigh Expectations Hurt CSL
The major report of the day yesterday came from the country’s premier healthcare and tech stock – CSL Ltd, but while the company out performed its guidance, it missed slightly on some analyst and market estimates and the shares were weaker.
Read MoreCSL Confirms Buyback
As expected Australia’s biggest pharma company, CSL will buy back up to $500 million worth of shares for the next year in what is now a regular occurrence.
Read MoreTime to Sell CSL?
According to a report in the Financial Times this morning researchers in the US and the Netherlands claim to have made a breakthrough in the search for a universal flu vaccine.
Read MoreCSL Continues To Spend Big
Australia’s CSL Ltd (CSL), the world’s largest blood products company, said says it has agreed to buy Novartis AG’s global influenza vaccine business for $US275 million.
Read More
